Search results for "peg-interferon and ribavirin"

showing 3 items of 3 documents

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.

2013

Summary We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naive patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09–4.30; P = 0.039) and C/C genotype rs12979860…

MaleHCV-RNA levelsHepacivirusHepacivirusLogistic regressionGastroenterologyCohort Studieschemistry.chemical_compoundPegylated interferonGenotypeantiviral therapygenderProspective Studiespeg-interferon and ribavirinProspective cohort studybiologysustained virologic responsevirus diseaseschronic hepatitis C; gender; HCV-RNA levels; IL28B polymorphisms; peg-interferon and ribavirin; sustained virologic responseMiddle AgedViral LoadTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleViral loadHCV-RNA levels; IL28B polymorphisms; chronic hepatitis C; gender; peg-interferon and ribavirin; sustained virologic response; Adult; Aged; Cohort Studies; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Loadmedicine.drugAdultmedicine.medical_specialtySex FactorsVirologyInternal medicineRibavirinmedicineHumanschronic hepatitis CRapid Virologic ResponseAgedHepatologybusiness.industryRibavirinHepatitis C Chronicbiology.organism_classificationdigestive system diseaseschemistryImmunologyInterferonsIL28B polymorphismsbusiness
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct